New hope for survivors of stroke and traumatic brain injury

CNS Drugs

Volumn 26, Issue 12, 2012, Pages 1071-1072

  Clark, Ian ^a  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ETANERCEPT; GLOBULIN;

CEREBROVASCULAR ACCIDENT; CHOROID PLEXUS; COGNITION; CROHN DISEASE; DRUG MECHANISM; HUMAN; NEUROTOXICITY; NOTE; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; SURVIVOR; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN INJURIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; STROKE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873444843     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-012-0014-1     Document Type: Note

References (15)

1. Hachinski V, Donnan GA, Gorelick PB, et al. Stroke: working toward a prioritized world agenda. Int J Stroke. 2010;5(4):238-56.
2. Tobinick EL, Gross H, Weinberger A, et al. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed Neurol Neurosurg. 2006;8(2):25.
3. Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflamm. 2008;5:2.
4. Batson O. The function of the vertebral veins and their role in the spread of metastases. Ann Surg. 1940;112:138-49.
5. Wen TS, Randall DC, Zolman JF. Protein accumulation in cerebrospinal fluid during -90 degrees head-down tilt in rabbit. J Appl Physiol. 1994;77(3):1081-6.
6. Qin LY, Wu XF, Block ML, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 2007;55(5):453-62.
7. Kaushal V, Schlichter LC. Mechanisms of microglia-mediated neurotoxicity in a new model of the stroke penumbra. J Neurosci. 2008;28(9):2221-30.
8. Clark IA, Alleva LM, Vissel B. The roles of TNF in brain dysfunction and disease. Pharmacol Ther. 2010;128:519-48.
9. Simpkins JW, Gatson JW, Wigginton JG. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Rationale and recommendations for first evaluating anti-Alzheimer's disease medications in acute brain injury patients. Alzheimers Dement. 2009;5(2):143-6.
10. Chio CC, Lin JW, Chang MW, et al. Therapeutic evaluation of etanercept in a model of traumatic brain injury. J Neurochem. 2010;115:921-9.
11. Baratz R, Tweedie D, Rubovitch V, et al. Tumor necrosis factor-alpha synthesis inhibitor, 3,6′-dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice. J Neurochem. 2011;118(6):1032-42.
12. Tobinick E. Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases. CNS Drugs. 2011;25(2):145-55.
13. Alkam T, Nitta A, Mizoguchi H, et al. Restraining tumor necrosis factor-alpha by thalidomide prevents the amyloid beta-induced impairment of recognition memory in mice. Behav Brain Res. 2008;189(1):100-6.
14. Zhou QH, Boado RJ, Hui EK, et al. Brain-penetrating tumor necrosis factor decoy receptor in the mouse. Drug Metab Dispos. 2011;39(1):71-6.
15. Russo I, Caracciolo L, Tweedie D, et al. 3,6′-Dithiothalidomide, a new TNF-alpha synthesis inhibitor, attenuates the effect of Abeta(1-42) intracerebroventricular injection on hippocampal neurogenesis and memory deficit. J Neurochem. 2012;122(6):1181-92.